Roche said it will start a Phase 2 trial combining petrelintide and enicepatide this year, targeting obesity with an eye toward differentiating safety and efficacy across its amylin-based program. The company framed the pairing as a potential best-in-class opportunity if the two incretin and amylin-pathway mechanisms act synergistically. The announcement came around ADA 2026 coverage, underscoring how Roche is advancing next-stage development decisions for obesity assets with ongoing competition in GLP-1-based regimens.